Related Experiment Videos
Long-term treatment of macroprolactinomas with CV 205-502
A Kvistborg1, J Halse, S Bakke
1Medical Department B, Rikshospitalet, National Hospital, Oslo, Norway.
Acta Endocrinologica
|April 1, 1993
Summary
CV 205-502 effectively treats macroprolactinomas by reducing prolactin levels and tumor size. This non-ergot dopamine agonist offers significant symptom improvement and is a well-tolerated alternative to bromocriptine.
Area of Science:
- Endocrinology
- Pharmacology
- Oncology
Background:
- Macroprolactinomas are pituitary tumors that secrete prolactin.
- Elevated prolactin levels can cause significant health issues, including hormonal imbalances and tumor growth.
Purpose of the Study:
- To evaluate the long-term efficacy and tolerability of CV 205-502 in patients with macroprolactinomas.
- To compare CV 205-502 with bromocriptine for macroprolactinoma treatment.
Main Methods:
- A 36-month study involving 16 patients with macroprolactinomas.
- Assessment of prolactin levels, tumor size, visual function, and hormonal status.
- Monitoring of adverse reactions and patient-reported outcomes.
Main Results:
- CV 205-502 normalized or suppressed prolactin in 12 of 16 patients.
- Tumor size decreased in 13 patients, and visual function normalized in all six with defects.
- Improvements observed in gonadal function, galactorrhea, and general well-being.
- Adverse effects occurred in 15 patients, leading to discontinuation in one case.
Conclusions:
- CV 205-502 is an effective and generally well-tolerated treatment for macroprolactinomas.
- It demonstrates superiority over bromocriptine in some patients and is a viable alternative when bromocriptine fails.